Did Eli Lilly Just Get a Leg Up on Novo Nordisk?
Eli Lilly and Novo Nordisk compete in the diabetes and obesity care markets. Outside of weight loss, Lilly also has a strong portfolio of medicines used in cancer, plaque psoriasis, and more.
Should You Buy Eli Lilly Stock After Another Major Win?
Eli Lilly has earned approval for an Alzheimer's disease therapy. It's yet another blockbuster drug for its lineup.
Will Wall Street Darling Eli Lilly's Stock Split Next?
Eli Lilly (NYSE: LLY) stock has been a winner for investors of late, owing largely to strong consumer demand for obesity drugs.
Better Growth Play: Eli Lilly vs. Vanguard Growth Index Fund ETF Shares
Growth stocks have been in the spotlight since 1995. This year, Eli Lilly and the Vanguard Growth Index Fund ETF Shares have been top performers in the category.
Eli Lilly could be next to cross $1 trillion mark, says Jim Cramer
'Mad Money' host Jim Cramer looks at what companies are in the running to join the elite $1 trillion club.
3 Pharma Stocks That Could Make Your Grandchildren Rich
Pharmaceutical stocks have not set the world on fire, with a few exceptions. Since the pandemic ended, pharma stocks have largely fallen out of favor with investors amid declining sales and mixed f...
3 Moonshot Stocks With the Potential to Turn $10K Into $1 Million
With the Nasdaq and S&P 500 on a running spree, it is easy to pick stocks on momentum. But if you are investing for the long term, you need to pick stocks that will grow your money at little risk.
Study Shows Lilly's (LLY) Obesity Drug More Effective Than NVO's
Data from a new study, also published on the JAMA website, shows that patients taking Lilly's (LLY) obesity drug are likely to lose more weight than those taking Novo's drug.
Novo Nordisk's stock slumps after study finds Wegovy lags Lilly's Mounjaro in speed and scale of weight loss
The stock of Danish biotech Novo Nordisk was down 1.6% premarket Tuesday, after a study found that the company's obesity drug Wegovy lags its main rival, Eli Lilly & Co. Inc.'s Mounjaro, in speed a...
Is Eli Lilly Stock a No-Brainer Buy After Its FDA Alzheimer's Disease Drug Win?
Lilly's recently approved Alzheimer's disease drug Kisunla could generate peak annual sales of close to $5 billion. However, the drugmaker has even more important growth drivers than Kisunla.
Novo Nordisk shares down after analysis finds Lilly drug leads to better weight loss
Shares in Novo Nordisk , maker of the wildly popular obesity drug Wegovy were down 1.1% on Tuesday after the publication of a data analysis showing rival Eli Lilly's own treatment Mounjaro leads to...
Biggest indicators for weight loss drugs are yet to come, says Jim Cramer
'Mad Money' host Jim Cramer talks today's massive tech run into a record close and how non-tech players are pushing toward the top.
Patients Lost More Weight On Eli Lilly's Mounjaro Than Novo Nordisk's Ozempic
Patients lost more significantly more weight on Eli Lilly's Mounjaro than Novo Nordisk's Ozempic, according to a new study.
Here's Why Eli Lilly (LLY) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Recession Alert: Play Defense While Earning Up To 10% Yield
Don't fear recessions; embrace them with a well-constructed portfolio. Market prices and business fundamentals are distinct elements. Focus on the latter. We discuss two picks from non-discretionar...
Related Companies